Connect Biopharma is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research.

With operations and expertise in China, the United States and Australia and clinical development activities in those geographies as well as Europe, Connect Biopharma is building a rich pipeline of internally designed, wholly owned small molecules and antibodies targeting several aspects of T cell biology. Our core expertise is in the use of functional cellular assays with T cells to screen and discover potent drug candidates against immune targets. Our two most advanced clinical-stage programs include potentially differentiated product candidates against validated targets.

Stock Quote

Today's Open
Previous Close

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Contact

David Carey (IR)
Lazar FINN Partners
Tel: +1 (212) 867-1768